pharmaphorum

MARCH 31, 2021

Novartis has added to its pipeline of radiopharmaceuticals pipeline once again, licensing a series of agents from iTheranostics that can be used to show where tumours are located in the body. . billion to buy targeted radioligand therapy Lu-PSMA-617 from Endocyte , shortly after encouraging results in a phase 2 prostate cancer trial.

Licensing 98

Licensing Licensing Gene Therapy Sales 98

pharmaphorum

APRIL 7, 2021

In its second licensing deal in the radio-oncology area in consecutive weeks, Novartis has agreed a $1.3 Novartis has made radioligands one of four pillars of its cancer business, along with cell and gene therapy, targeted drugs and immunotherapeutics, and has been steadily bolting on assets to expand its pipeline in this area.

DNA 52

DNA Licensing Licensing Gene Therapy 52

The Pharma Data

AUGUST 5, 2021

Bayer recently formed its own cell and gene therapy platform as part of its transformation strategy for Pharmaceuticals. The platform already has potentially ground-breaking medical innovations in clinical development, such as a therapy for the treatment of Parkinson’s. Pharmaceuticals raises sales and earnings.

Sales 52

Sales Production Gene Therapy Allergies 52